BrainCheck Secures $13M to Advance AI Cognitive Care Infrastructure
March 3, 2026, 3:34 am
BrainCheck recently raised $13 million in Series A funding. This investment propels its AI-assisted cognitive care platform forward. The company aims to expand infrastructure, enhancing patient monitoring and population-scale deployment. Its FDA-cleared digital assessment tool supports early detection of mild cognitive impairment and Alzheimer’s disease. BrainCheck focuses on value-based care models, integrating seamlessly with electronic health records. It serves over 500 healthcare organizations, streamlining comprehensive cognitive health pathways. The capital ensures robust, scalable solutions for evolving clinical needs.
BrainCheck, a leader in digital cognitive assessment, has secured an additional $13 million in Series A financing. This significant capital infusion will expand its innovative AI-enabled cognitive care platform. The investment round was led by Next Coast Ventures. S3 Ventures and UPMC Enterprises also participated. This funding marks a pivotal moment for the company. It solidifies its position in the rapidly evolving digital health sector.
The Austin- and New York-based firm develops a robust digital platform. It focuses on comprehensive cognitive assessment and care. Its flagship product is BrainCheck Assess™. This is an FDA Class II digital cognitive assessment. It provides critical data for clinicians. The platform is designed for real-world clinical use.
New capital fuels several key initiatives. BrainCheck will deepen workflow integration. It will enhance longitudinal patient monitoring capabilities. Population-scale deployment across various healthcare settings is a priority. This includes primary care and specialty clinics. The company will also advance its AI-assisted clinical infrastructure. This infrastructure is tailored for value-based and risk-bearing healthcare environments.
BrainCheck is expanding its partnerships. It collaborates with care organizations. These alliances aim to operationalize cognitive care delivery. Many practices lack necessary staffing or infrastructure. BrainCheck provides a solution. These partnerships extend the company’s model. It moves beyond just assessment. It creates structured, scalable cognitive care pathways. Digital tools combine with operational enablement. This supports providers comprehensively.
The platform boasts impressive adoption. Over 500 healthcare organizations nationwide use it. Clinicians have completed more than 640,000 cognitive assessments. BrainCheck Assess™ drives this widespread usage. The system features 29 validated cognitive screeners. It also includes essential care planning tools. These tools ensure standardized, repeatable measurements. They enable crucial longitudinal tracking.
Testing protocols are highly customizable. They are available in both English and Spanish. Seamless integration into electronic health record (EHR) systems is a core feature. This reduces operational friction. It ensures efficient data flow within clinical environments. Major institutions like UPMC and Bon Secours utilize the platform. Numerous research hospitals also rely on its capabilities.
Healthcare is undergoing a paradigm shift. Value-based care and risk-sharing models are gaining traction. This new landscape emphasizes outcomes over volume. Standardized cognitive assessment is increasingly important. It serves as an entry point. It facilitates earlier identification of mild cognitive impairment (MCI). It also aids in detecting dementia-related diseases. This includes Alzheimer’s disease.
BrainCheck’s infrastructure is specifically engineered for population-scale cognitive care. It enables earlier risk identification. It provides objective measurement over time. AI-assisted longitudinal analysis offers profound insights. It fosters coordinated care across clinical teams. This comprehensive approach addresses critical needs.
The company's strategy focuses on practical clinical application. It reduces operational friction in time-constrained settings. This is paramount for busy healthcare professionals. Clinical interpretation remains physician-directed. AI assists decision-making. It does not replace it. This responsible use of technology builds trust. It empowers clinicians.
Early detection of cognitive decline holds immense value. For Accountable Care Organizations (ACOs), it is a financial imperative. Managing cognitive health longitudinally prevents costly downstream hospitalizations. It averts catastrophic care expenses. BrainCheck provides the standardized infrastructure for this. It allows these models to operate effectively.
The current landscape for dementia diagnosis is evolving. Historically, it was a slow process. Paper-based tests and long specialist waits were common. Now, new tools emerge. Blood-based biomarkers offer promise. Targeted therapies for Alzheimer’s disease are on the horizon. These advancements demand earlier, highly accurate risk stratification.
BrainCheck Assess™ positions itself as the critical front door. It streamlines this new care continuum. Primary care doctors can establish objective baselines rapidly. The platform's integration with EHRs ensures seamless operations. Results inform lab orders, referrals, and structured follow-up care. This creates a more efficient, patient-centered pathway.
This investment underscores a vital trend. Digital health solutions are transforming patient care. They offer scalable, accessible tools. BrainCheck leads this transformation in cognitive health. Its platform delivers consistency and objectivity. It provides longitudinal insights into cognitive decline. This supports a proactive, preventative healthcare model. The company's future looks bright. It aims to deliver advanced cognitive care to a broader population.
BrainCheck, a leader in digital cognitive assessment, has secured an additional $13 million in Series A financing. This significant capital infusion will expand its innovative AI-enabled cognitive care platform. The investment round was led by Next Coast Ventures. S3 Ventures and UPMC Enterprises also participated. This funding marks a pivotal moment for the company. It solidifies its position in the rapidly evolving digital health sector.
The Austin- and New York-based firm develops a robust digital platform. It focuses on comprehensive cognitive assessment and care. Its flagship product is BrainCheck Assess™. This is an FDA Class II digital cognitive assessment. It provides critical data for clinicians. The platform is designed for real-world clinical use.
New capital fuels several key initiatives. BrainCheck will deepen workflow integration. It will enhance longitudinal patient monitoring capabilities. Population-scale deployment across various healthcare settings is a priority. This includes primary care and specialty clinics. The company will also advance its AI-assisted clinical infrastructure. This infrastructure is tailored for value-based and risk-bearing healthcare environments.
BrainCheck is expanding its partnerships. It collaborates with care organizations. These alliances aim to operationalize cognitive care delivery. Many practices lack necessary staffing or infrastructure. BrainCheck provides a solution. These partnerships extend the company’s model. It moves beyond just assessment. It creates structured, scalable cognitive care pathways. Digital tools combine with operational enablement. This supports providers comprehensively.
The platform boasts impressive adoption. Over 500 healthcare organizations nationwide use it. Clinicians have completed more than 640,000 cognitive assessments. BrainCheck Assess™ drives this widespread usage. The system features 29 validated cognitive screeners. It also includes essential care planning tools. These tools ensure standardized, repeatable measurements. They enable crucial longitudinal tracking.
Testing protocols are highly customizable. They are available in both English and Spanish. Seamless integration into electronic health record (EHR) systems is a core feature. This reduces operational friction. It ensures efficient data flow within clinical environments. Major institutions like UPMC and Bon Secours utilize the platform. Numerous research hospitals also rely on its capabilities.
Healthcare is undergoing a paradigm shift. Value-based care and risk-sharing models are gaining traction. This new landscape emphasizes outcomes over volume. Standardized cognitive assessment is increasingly important. It serves as an entry point. It facilitates earlier identification of mild cognitive impairment (MCI). It also aids in detecting dementia-related diseases. This includes Alzheimer’s disease.
BrainCheck’s infrastructure is specifically engineered for population-scale cognitive care. It enables earlier risk identification. It provides objective measurement over time. AI-assisted longitudinal analysis offers profound insights. It fosters coordinated care across clinical teams. This comprehensive approach addresses critical needs.
The company's strategy focuses on practical clinical application. It reduces operational friction in time-constrained settings. This is paramount for busy healthcare professionals. Clinical interpretation remains physician-directed. AI assists decision-making. It does not replace it. This responsible use of technology builds trust. It empowers clinicians.
Early detection of cognitive decline holds immense value. For Accountable Care Organizations (ACOs), it is a financial imperative. Managing cognitive health longitudinally prevents costly downstream hospitalizations. It averts catastrophic care expenses. BrainCheck provides the standardized infrastructure for this. It allows these models to operate effectively.
The current landscape for dementia diagnosis is evolving. Historically, it was a slow process. Paper-based tests and long specialist waits were common. Now, new tools emerge. Blood-based biomarkers offer promise. Targeted therapies for Alzheimer’s disease are on the horizon. These advancements demand earlier, highly accurate risk stratification.
BrainCheck Assess™ positions itself as the critical front door. It streamlines this new care continuum. Primary care doctors can establish objective baselines rapidly. The platform's integration with EHRs ensures seamless operations. Results inform lab orders, referrals, and structured follow-up care. This creates a more efficient, patient-centered pathway.
This investment underscores a vital trend. Digital health solutions are transforming patient care. They offer scalable, accessible tools. BrainCheck leads this transformation in cognitive health. Its platform delivers consistency and objectivity. It provides longitudinal insights into cognitive decline. This supports a proactive, preventative healthcare model. The company's future looks bright. It aims to deliver advanced cognitive care to a broader population.